Abstract

REVIEW ON-RHEUMATOID ARTHRITIS

Saba Shaikh*, Ravi Dubey, Dr.Y.M Joshi and Dr. Vilasrao J. Kadam

ABSTRACT

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of the tissue around the joints,as well as in other organs in the body.Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors are involve in the diagnosis and prognosis of rheumatoid arthritis.RA traditionally been treated using pyramid approach,in which non-steroidal anti-inflammatory (NSAIDs) are the first line treatment and disease modifying anti-rheumatic drugs (DMARDs) are introduced relatively late in the disease.The treatment of RA has been revolutionized by advances in the understanding of its pathologic mechanisms and the development of drugs which target them.Biologic therapies have provided clear advance in the treatment of rheumatological conditions.Currently available TNF-targeting biologic agents that are licensed for at least one of the above-named diseases are etanercept, infliximab, adalimumab, golimumab, and certolizumab.Biologic agents with a different mechanism of action have also been approved in rheumatoid arthritis (rituximab, abatacept, and tocilizumab).Although these biologic agents are highly effective,there is a need for improved management strategies. Researchers are also developing molecules–for example,the Janus kinase inhibitor CP-690550 (tofacitinib) to target other aspects of the inflammatory cascade.

Keywords: Rheumatoid arthritis, Biologic therapy, DMARDs, Kinase inhibitor,TNF inhibitors.